title: [Transition from prostacyclin to bosentan in five patients with severe pulmonary hypertension: the switch is possible].
abstract: Prostacyclin improves symptoms, exercise tolerance, and survival in patients with pulmonary arterial hypertension. However, the difficulty of administration (whether intravenous, subcutaneous, or by inhalation) often causes side effects that can reduce the patient's quality of life and which may sometimes be serious. Bosentan, an orally active endothelin receptor antagonist, improves functional class and exercise tolerance in these patients. We describe the successful transition from prostacyclin to bosentan in five patients with severe pulmonary arterial hypertension who suffered serious side effects with prostacyclin treatment.
authors.affiliation: Servicio de Cardiología, Unidad de Hipertensión Pulmonar, Insuficiencia Cardiaca y Trasplante Cardiaco, Hospital Universitario 12 de Octubre, Madrid, España. angelaflox@gmail.com
authors.forename: Angela
authors.initials: A
authors.lastname: Flox Camacho
authors.forename: Pilar
authors.initials: P
authors.lastname: Escribano Subías
authors.forename: Rocío
authors.initials: R
authors.lastname: Tello de Meneses
authors.forename: Juan
authors.initials: J
authors.lastname: Delgado Jiménez
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Gómez Sánchez
authors.forename: Carlos
authors.initials: C
authors.lastname: Sáenz de la Calzada
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D011464:Epoprostenol; D000077300:Bosentan